A new study using botulinum neurotoxin type A (BoNTA), conducted by the Department of Uro-Neurology at the University College London Hospital, revealed impressive results in patients with mixed cases of incontinence.
The botulinum neurotoxin type A (BoNTA) is a variation of the commonly known Botox.
Seventy-four patients (51 women, 23 men) with refractory IDO incontinence were treated with intradetrusor injections of 200 U BoNTA, they were then evaluated in a non-randomised, open-label, cohort study.
Patients with urinary frequency, urge incontinence and stress incontinence were assessed using the condition-specific Urogenital Distress Inventory (UDI 6) before and 4 weeks after the BoNTA treatment.
The outcome of complete continence was 51% (38 of 74) 4 weeks after intradetrusor injections of BoNTA.
In patients who were not completely continent, the scores show their conditions of urinary frequency, urge incontinence and stress incontinence were all reduced significantly. The inclusion of patients with mixed incontinence may have resulted in underestimation of the complete continence rate.
50% of patients reporting complete continence 4 weeks after BoNTA treatment reveal the effiency of this emerging treatment for patients with refractory IDO incontinence.
Furthermore, in those whom complete continence was not achieved, there was a notable and significant reduction in reported urge incontinence, stress incontinence, and urinary frequency.
Story source http://www.urotoday.com/
A new study using botulinum neurotoxin type A (BoNTA), conducted by the Department of Uro-Neurology at the University College London Hospital, revealed impressive results in patients with mixed cases of incontinence.
The botulinum neurotoxin type A (BoNTA) is a variation of the commonly known Botox.
Seventy-four patients (51 women, 23 men) with refractory IDO incontinence were treated with intradetrusor injections of 200 U BoNTA, they were then evaluated in a non-randomised, open-label, cohort study.
Patients with urinary frequency, urge incontinence and stress incontinence were assessed using the condition-specific Urogenital Distress Inventory (UDI 6) before and 4 weeks after the BoNTA treatment.
The outcome of complete continence was 51% (38 of 74) 4 weeks after intradetrusor injections of BoNTA.
In patients who were not completely continent, the scores show their conditions of urinary frequency, urge incontinence and stress incontinence were all reduced significantly. The inclusion of patients with mixed incontinence may have resulted in underestimation of the complete continence rate.
50% of patients reporting complete continence 4 weeks after BoNTA treatment reveal the effiency of this emerging treatment for patients with refractory IDO incontinence.
Furthermore, in those whom complete continence was not achieved, there was a notable and significant reduction in reported urge incontinence, stress incontinence, and urinary frequency.
Story source http://www.urotoday.com/